Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...

An HHS spokesperson said the agency has not yet made a final decision regarding changes to the COVID-19 vaccination ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies ...